Joseph M. Tuscano

6.3k total citations
150 papers, 4.3k citations indexed

About

Joseph M. Tuscano is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Joseph M. Tuscano has authored 150 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Pathology and Forensic Medicine, 54 papers in Oncology and 46 papers in Genetics. Recurrent topics in Joseph M. Tuscano's work include Lymphoma Diagnosis and Treatment (59 papers), Chronic Lymphocytic Leukemia Research (45 papers) and CAR-T cell therapy research (19 papers). Joseph M. Tuscano is often cited by papers focused on Lymphoma Diagnosis and Treatment (59 papers), Chronic Lymphocytic Leukemia Research (45 papers) and CAR-T cell therapy research (19 papers). Joseph M. Tuscano collaborates with scholars based in United States, Canada and France. Joseph M. Tuscano's co-authors include John H. Kehrl, Robert T. OʼDonnell, Thomas F. Tedder, Ted Wun, Shinichi Sato, Thomas M. Habermann, Kit S. Lam, Carol M. Richman, Dennis Pietronigro and Izidore S. Lossos and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Accounts of Chemical Research.

In The Last Decade

Joseph M. Tuscano

143 papers receiving 4.2k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Joseph M. Tuscano 1.4k 1.3k 1.1k 932 777 150 4.3k
Jon P. Gockerman 879 0.6× 1.5k 1.2× 836 0.8× 875 0.9× 908 1.2× 128 4.4k
K. Höffken 967 0.7× 2.6k 2.0× 1.1k 1.0× 788 0.8× 748 1.0× 186 5.4k
Lothar Bergmann 798 0.6× 1.4k 1.0× 2.1k 1.9× 1.0k 1.1× 662 0.9× 182 4.8k
Thomas S. Lin 2.3k 1.7× 1.6k 1.2× 1.4k 1.3× 1.5k 1.6× 2.5k 3.3× 182 5.2k
Ann T. Farrell 632 0.5× 2.5k 1.9× 2.8k 2.6× 936 1.0× 665 0.9× 75 6.7k
Samuel A. Jacobs 753 0.6× 1.4k 1.1× 620 0.6× 273 0.3× 356 0.5× 143 2.9k
Grzegorz S. Nowakowski 3.3k 2.4× 3.4k 2.6× 1.3k 1.2× 1.2k 1.3× 1.6k 2.1× 346 6.3k
Clive S. Zent 2.9k 2.2× 881 0.7× 966 0.9× 2.2k 2.4× 3.5k 4.5× 192 5.3k
Fabio Benedetti 1.0k 0.7× 943 0.7× 714 0.7× 616 0.7× 370 0.5× 164 3.1k
Michelle M. Lilly 1.4k 1.1× 1.3k 1.0× 2.4k 2.2× 600 0.6× 303 0.4× 103 4.4k

Countries citing papers authored by Joseph M. Tuscano

Since Specialization
Citations

This map shows the geographic impact of Joseph M. Tuscano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph M. Tuscano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph M. Tuscano more than expected).

Fields of papers citing papers by Joseph M. Tuscano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph M. Tuscano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph M. Tuscano. The network helps show where Joseph M. Tuscano may publish in the future.

Co-authorship network of co-authors of Joseph M. Tuscano

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph M. Tuscano. A scholar is included among the top collaborators of Joseph M. Tuscano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph M. Tuscano. Joseph M. Tuscano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rosenberg, Aaron S., Emanual Maverakis, Caitlin Costello, et al.. (2025). Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis. PubMed. 2(3). 100067–100067.
2.
Jonas, Brian A., Peter Curtin, Gary J. Schiller, et al.. (2025). A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503). Leukemia Research. 155. 107717–107717.
3.
Jonas, Brian A., Zarir E. Karanjawala, Mehrdad Abedi, et al.. (2024). Updated Results of a Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia. Blood. 144(Supplement 1). 1503–1503. 1 indexed citations
4.
Gopal, Ajay K., et al.. (2024). A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma. The Oncologist. 29(4). 278–288. 4 indexed citations
5.
Tuscano, Joseph M., et al.. (2023). Checkpoint inhibition in hematologic malignancies. Frontiers in Oncology. 13. 1288172–1288172. 6 indexed citations
6.
Park, Sunmin, et al.. (2023). Intravenous IL-1 Receptor Antagonist for Prevention of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome. Blood. 142(Supplement 1). 4858–4858. 1 indexed citations
7.
Meckler, Joshua F., et al.. (2023). A Fermented Wheat Germ Extract Contains Protein Components Active against NSCLC Xenografts In Vivo. Current Issues in Molecular Biology. 45(9). 7087–7096. 1 indexed citations
8.
Poh, Christina, John D. McPherson, Joseph M. Tuscano, et al.. (2022). Environmental pesticide exposure and non-Hodgkin lymphoma survival: a population-based study. BMC Medicine. 20(1). 165–165. 7 indexed citations
9.
10.
Rosenberg, Aaron S., Ann Brunson, Joseph M. Tuscano, et al.. (2021). Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. Blood Cancer Journal. 11(1). 5–5. 13 indexed citations
11.
DAVIS, JULIAN R., et al.. (2020). A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. Clinical Lymphoma Myeloma & Leukemia. 20(7). 453–458. 3 indexed citations
12.
Barisone, Gustavo A., et al.. (2020). Bispecific anti-CD22 T-cell engager efficiently promotes cell-mediated cytotoxicity of lymphoma, leukemia and sarcoma targets. The Journal of Immunology. 204(1_Supplement). 239.27–239.27. 2 indexed citations
13.
Tuscano, Joseph M., Emanual Maverakis, Susan Groshen, et al.. (2019). A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma. Clinical Cancer Research. 25(23). 7004–7013. 34 indexed citations
14.
Poh, Christina, Paul Frankel, Christopher Ruel, et al.. (2019). Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis. Blood. 134(Supplement_1). 760–760. 25 indexed citations
15.
Rosenberg, Aaron S., Thierry Façon, Safiya Abouzaid, et al.. (2017). Morbid Progression Is Common Among Patients with Multiple Myeloma and Is Associated with Shortened Overall Survival: Validation of the Progression-Free Survival Endpoint. Blood. 130. 3113–3113. 1 indexed citations
16.
17.
Wiernik, Peter H., Izidore S. Lossos, Joseph M. Tuscano, et al.. (2008). Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. 26(30). 4952–4957. 300 indexed citations
18.
Chan, James W., Douglas S. Taylor, Stephen M. Lane, et al.. (2007). Non-destructive Identification of Individual Leukemia Cells by Optical Trapping Raman Spectroscopy. University of North Texas Digital Library (University of North Texas). 1 indexed citations
19.
Martel, Cynthia L., Soumya M. Reddy, Carla Greco, et al.. (2002). Isolated cavernous sinus extramedullary relapse of chronic myelogenous leukemia following allogeneic stem cell transplant. Annals of Hematology. 81(2). 108–110. 7 indexed citations
20.
Tuscano, Joseph M., Thomas F. Tedder, & John H. Kehrl. (1996). Engagement of the adhesion receptor cd22 triggers a potent stimulatory signal for b cells and blocking cd22/cd22l interactions impairs t-cell proliferation. The FASEB Journal. 10(6). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jon P. Gockerman Breakdown of academic impact, for papers by K. Höffken Breakdown of academic impact, for papers by Lothar Bergmann Breakdown of academic impact, for papers by Thomas S. Lin Breakdown of academic impact, for papers by Ann T. Farrell Breakdown of academic impact, for papers by Samuel A. Jacobs Breakdown of academic impact, for papers by Grzegorz S. Nowakowski Breakdown of academic impact, for papers by Clive S. Zent Breakdown of academic impact, for papers by Fabio Benedetti Breakdown of academic impact, for papers by Michelle M. Lilly
Rankless by CCL
2026